Deutsche Bank AG Increases Holdings in Kiniksa Pharmaceuticals International, plc $KNSA

Key Points

• Deutsche Bank AG increased its stake in Kiniksa Pharmaceuticals by 177.1%, acquiring an additional 252,125 shares for a total of 394,522 shares valued at approximately $8.76 million.
• Brokerage firms have issued positive ratings for Kiniksa Pharmaceuticals, with Wells Fargo raising their price target from $30.00 to $42.00 and Jefferies increasing theirs from $45.00 to $54.00.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share for the last quarter, surpassing analyst expectations of $0.18, with total revenue of $156.80 million.

Deutsche Bank AG lifted its position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 177.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 394,522 shares of the company's stock after purchasing an additional 252,125 shares during the quarter. Deutsche Bank AG owned 0.54% of Kiniksa Pharmaceuticals International worth $8,762,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. GAMMA Investing LLC grew its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares in the last quarter. US Bancorp DE bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $33,000. Asset Management One Co. Ltd. bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $41,000. Wealthquest Corp bought a new position in shares of Kiniksa Pharmaceuticals International during the 1st quarter worth $42,000. Finally, Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International during the 4th quarter worth $61,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

KNSA has been the topic of a number of recent research reports. Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Wall Street Zen raised Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Jefferies Financial Group raised their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a report on Tuesday, July 29th. Finally, Wells Fargo & Company raised their price target on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a report on Wednesday, July 9th. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has a consensus rating of "Buy" and an average price target of $41.17.

Insider Buying and Selling

In other news, Director Thomas Malley sold 78,233 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $33.09, for a total value of $2,588,729.97. Following the completion of the transaction, the director owned 12,546 shares in the company, valued at $415,147.14. This trade represents a 86.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Ross Moat sold 27,594 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the completion of the transaction, the insider owned 9,415 shares of the company's stock, valued at approximately $273,223.30. The trade was a 74.56% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 663,486 shares of company stock worth $20,727,713 over the last quarter. Company insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

KNSA traded down $0.55 on Tuesday, hitting $33.17. 220,253 shares of the company were exchanged, compared to its average volume of 691,366. The firm has a fifty day simple moving average of $29.43 and a two-hundred day simple moving average of $25.18. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $34.55. The stock has a market capitalization of $2.46 billion, a PE ratio of 830.08 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. On average, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.